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Abstract
Introduction Recently, it has been shown in several
experimental settings that the noble gases xenon and helium
have neuroprotective properties. In this study we tested the
hypothesis that the noble gas argon has a neuroprotective
potential as well. Since traumatic brain injury and stroke are
widespread and generate an enormous economic and social
burden, we investigated the possible neuroprotective effect in in
vitro models of traumatic brain injury and cerebral ischemia.
Methods Organotypic hippocampal slice cultures from mice
pups were subjected to either oxygen-glucose deprivation or to
a focal mechanical trauma and subsequently treated with three
different concentrations (25, 50 and 74%) of argon immediately
after trauma or with a two-or-three-hour delay. After 72 hours of
incubation tissue injury assessment was performed using
propidium iodide, a staining agent that becomes fluorescent
when it diffuses into damaged cells via disintegrated cell
membranes.
Results We could show argon's neuroprotective effects at
different concentrations when applied directly after oxygen-
glucose deprivation or trauma. Even three hours after
application, argon was still neuroprotective.
Conclusions Argon showed a neuroprotective effect in both in
vitro models of oxygen-glucose deprivation and traumatic brain
injury. Our promising results justify further in vivo animal
research.
Introduction
The first biological effects of argon were demonstrated as
early as 1939 [1]. Behnke et al. described the narcotic effects
of argon as experienced by deep sea divers at high pressures.
Half a century later Soldatov and co-workers [2] were the first
to show argon's protective effects under hypoxic conditions.
Thereafter, it was reported that argon shields hair cells from
ototoxic process [3] and protects cell cultures from ischemia
[4]. In contrast to argon, xenon's organ protective effects have
been investigated in various settings and models, ranging from
cell cultures to clinical trials. Xenon has proven to be a safe
anaesthetic agent and xenon's organoprotective properties
have been demonstrated in many fields [5-14].
Stroke and traumatic brain injury (TBI) are two very common
causes of death and disability worldwide and create a signifi-
cant economic and social burden [15-17]. While the acute
treatment of stroke today is highly standardized and secondary
prevention is effective, an efficient protection of the cells at risk
in the penumbra is lacking. This is particularly evident in regard
to TBI. Although an estimated 1.5 million people in the United
States suffer from TBI annually [15,17] due to the diverse
mechanisms of the initial trauma itself and the following molec-
ular pathways, a specific treatment is still absent.
When compared to xenon argon has some conspicuous
advantages: low cost; no narcotic effects at normobaric pres-
sures. Yet, data on argon's effects on cells are sparse.
ANOVA: analysis of variance; ATP: adenosine triphosphate; EM: experimental medium; GABA: gamma-aminobutyric acid; NMDA: N-methyl-D-aspar-
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Therefore, we tested the effect of argon in in vitro models that
involved either a focal mechanical trauma or oxygen-glucose
deprivation of cultured hippocampal slices.
Materials and methods
All experiments were performed in compliance with the local
Institutional Ethical Review Committee and have been
approved by the animal protection representative at the Insti-
tute of Animal Research at the RWTH Aachen University Hos-
pital, according to the German animal protection law §4,
Section 3. Unless otherwise stated, all chemicals were
obtained from PAA Laboratories GmbH (Pasching, Austria).
Organotypic hippocampal slice cultures
Cultures were prepared as previously reported [18], with
some modifications [8,19]. Briefly, brains from six-to-eight-
day-old mice pups (C57BL/6N, Charles River Laboratories,
Sulzfeld, Germany) were extracted and directly transferred to
ice-cold preparation medium (Gey's balanced salt solution
(Sigma-Aldrich, Munich, Germany), 5 mg/ml D-(+)Glucose
(Roth, Karlsruhe, Germany), 0.1 Vol. % antibiotic/antimycotic
solution (penicillin G 10,000 units/ml, streptomycin sulphate
10 mg/ml, amphotericin B 25 μg/ml). The hippocampi were
rapidly removed from the brains, cut into 400 μm thick trans-
verse slices with a McIllwain tissue chopper (The Mickle Lab-
oratory Engineering Co. Ltd., Gomshall, UK) and arranged
onto the membrane of a MilliCell tissue culture insert (MilliCell-
CM, Millipore Corporation, Billerica, MA, USA). The inserts
were placed in tissue culture plates (Sarstedt, Newton, MA,
USA) and 0.8 ml growth medium (50% Eagle minimal essen-
tial medium with Earle's salts, 25% Hank's balanced salt solu-
tion (Sigma-Aldrich, Munich, Germany), 25% heat inactivated
horse serum, 2 mM L-glutamine, 5 mg/ml D-glucose, 1% anti-
biotic/antimycotic solution and 50 mM HEPES buffer solution
(Fluka, Buchs, Switzerland), titrated to pH 7.2) was inserted
underneath the membrane. The hippocampal slice cultures
were incubated for 14 days and growth medium was
exchanged every third day.
Oxygen glucose deprivation
After two weeks in culture the growth medium was exchanged
with experimental medium (EM). EM was similar to growth
medium but the horse serum was replaced in equal measure
by Eagle minimal essential medium. Additionally, to allow fluo-
rescence imaging, 4.5 μM propidium iodide (PI) (Sigma-
Aldrich, Munich, Germany) was added and the slices were
then incubated for 30 minutes at 37°C and 5% CO2. After
baseline fluorescence imaging, oxygen-glucose deprivation
(OGD) was accomplished as previously described [20,21]
with minor modifications. First, 50 ml of glucose free experi-
mental medium was saturated with 95% N2, 5% CO2. After
replacing the culture medium with the oxygen-glucose
deprived medium the plates were transferred into an airtight
pressure chamber (volume = 750 ml) equipped with inlet and
outlet valves. The chamber was immediately flushed with a
humidified gas mixture (5% CO2, 95% N2) for two minutes at
a flowrate of 2.5 l/min to ensure a >99% gas exchange in the
chamber which was then sealed. After 30 minutes of oxygen-
glucose deprivation at 37°C, the medium was replaced by EM
containing glucose and 4.5 μM PI. Immediately after the slices
were relocated to the pressure chamber, the chamber was
flushed with the experimental gas mixture and sealed.
Slices incubated for 72 hours in 5% CO2, 21% O2 and 74%
N2 were considered to be the OGD trauma control group. The
negative control (no OGD) was subjected to the identical
treatment. Yet the EM contained 5 mg/ml glucose and was
saturated with 5% CO2, 21% O2 and 74% N2 and the pres-
sure chamber was flushed with 5% CO2, 21% O2 and 74%
N2. For experimental groups, the pressure chamber was
flushed using a premixed argon gas mixture (5% CO2, 21%
O2, x% Argon, [74-x]% N2; Air Liquide Santé International,
Paris, France).
Traumatic brain injury
All slices subject to traumatic brain injury were first incubated
for 30 minutes at 37°C, 95% air and 5% CO2 in EM containing
4.5 μM PI. Following baseline fluorescence imaging the trau-
matic brain injury was generated using an apparatus designed
as previously described [8,19,22]. It allowed dropping a stylus
in a reproducible manner under stereomicroscopic supervi-
sion with a three-axis micromanipulator from a height of 7 mm
with a force of 5.26 μJ onto the CA1 region of the hippocam-
pal slices. The shape of the stylus was round to prevent pierc-
ing of the tissue. After traumatizing the CA1 region the
medium was changed to EM, containing 4.5 μM PI. The cul-
tures were then placed into the pressure chamber for 72 hours
before the final imaging. The TBI-trauma control group (that is,
traumatized) was incubated in an atmosphere of 5% CO2,
21% O2 and 74% N2. The negative control group, not subject
to TBI-trauma, followed the identical cycle to the trauma group,
but the pin was not dropped onto the slice. The pressure
chamber for experimental groups contained 5% CO2, 21%
O2, x% Argon and [74-x]% N2.
Staining and microscopy
Propidium iodide is a fluorescent intercalating agent which is
widely used to stain DNA [19,21,23]. While it is unable to pen-
etrate viable cells it can diffuse into damaged cells when the
membrane is disintegrated. Upon binding to the DNA it
becomes highly fluorescent. PI fluorescence was observed
with a fluorescence microscope (Zeiss Axioplan, Carl Zeiss
MicroImaging GmbH, Jena, Germany) and a low-power 4×
objective (Zeiss Achroplan 4×/0.10, Carl Zeiss MicroImaging
GmbH, Jena, Germany) and recorded with a digital camera
and appropriate software (SPOT Pursuit 4 MP Slider, Diag-
nostic Instruments Inc, Sterling Heights, MI, USA; MetaVue,
Molecular Devices, Sunnyvale, CA, USA). The exposure time
was adjusted to the fluorescence magnitude captured from a
standard slide (Fluor-Ref, Omega Optical, Brattleboro, VT,Available online http://ccforum.com/content/13/6/R206
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USA) to accommodate for the mercury lamp's fluctuating
intensity over time.
Assessment of cell injury
The fluorescence images were digitalized at eight bit, allowing
us to differentiate between a spectrum of 256 (from 0 to 255)
grey scale levels. Damaged regions with a high PI uptake emit-
ted at a high grey scale level, while vital regions showed only
minor emissions. The red channel of each image was analyzed
with ImageJ software (National Institutes of Health, Bethesda,
MD, USA) [24]. ImageJ generated a histogram for each image
which showed the absolute number of pixels with the same
grey scale value. Histograms from non-traumatized slices (see
Figure 1) showed that the vast majority of all pixels had grey
scale values between 10 and 100, representing mostly back-
ground fluorescence. In contrast, traumatized slices showed,
in addition to their background fluorescence, a well-defined
peak between 160 and 185. As in previous publications
[8,19,25,26] we established a threshold (in this instance at a
grey scale value of 100) which proved to be valid to distin-
guish between traumatized and non-traumatized cells. The
integration of all pixels exceeding the threshold therefore was
a sound quantification of cell injury.
Statistical Analysis
After measuring the induced cell damage for each slice, these
results were combined for every experimental group and then
normalized to the intensities of trauma in each trauma group
(OGD or TBI, respectively). Mean values and standard errors
of the means (SEM) were calculated with SPSS 16.0 (SPSS
Inc., Chicago, IL, USA). Statistical significance was evaluated
with SPSS using the one-way analysis of variance (ANOVA)
with bonferroni post-hoc analysis; P ≤ 0.05 was considered as
statistically significant.
Results
Tissue damage after 14 days of incubation was negligible (as
has been shown before, see Rossaint et al. [19]) otherwise
slices were excluded. A distinct pattern of distribution of pixel
values was evident for traumatized and non-traumatized
groups 72 hours after inducing the experimental injury. Both
groups shared a certain background fluorescence level after
OGD or TBI (Figure 1). Above a threshold of a grey scale value
of 100, the traumatized groups showed a characteristic peak
in fluorescence between pixel values of 160 to 185. Non-trau-
matized slices in both OGD- and TBI-models displayed a
minor, but still detectable, rise in emission at a similar lumi-
nance. All pixels above the threshold were summarized for
each group. The integral for OGD and TBI trauma control
groups was set as one and the sums for all further groups
were normalized to the OGD and TBI trauma control group
respectively as a quantitative measure for trauma intensity (see
inserts in Figure 1).
TBI produced less absolute tissue damage than OGD due to
the focal nature of this injury. Nevertheless the difference
between traumatized and non-traumatized groups was still
greater in TBI due to the very low damage found in non-trau-
matized TBI-slices. More than likely this can be attributed to a
longer and more strenuous procedure during OGD. While
there were only two medium changes necessary during TBI,
OGD slices were subjected to three exchanges. Furthermore
the pressure chamber had to be flushed twice for OGD,
exposing to a certain extent the surface of the slices to dehy-
dration. Therefore, the TBI control group reached only 6% of
the total trauma while the OGD control group showed almost
27.3% of maximum trauma intensity. After establishing a valid
measurement for tissue injury, we tested the effects of argon
on traumatized slices. We treated groups of slices with 25%,
50% or 74% argon after TBI or OGD was induced. Figure 2
demonstrates that argon provided a significant protective
effect in OGD as well as in TBI. After OGD, argon decreased
tissue injury by at least 40%. Figure 2, panel A shows the rela-
tionship between argon concentration and damage reduction
at 37°C. A concentration of 74% argon was most effective
(0.52 ± 0.05), yet at concentrations of 25% (0.60 ± 0.05) or
50% (0.56 ± 0.03) a significant reduction of trauma was
observed.
Argon showed neuroprotective potential in TBI (Figure 2,
panel B). The protection was most effective at a concentration
of 50% (0.14 ± 0.03); however, it was still effective at 25%
(0.37 ± 0.04) and 74% (0.66 ± 0.07) argon (see exemplary
fluorescence images for traumatized and non-traumatized con-
trol slices and slices treated with 50% argon in Figure 3).
To adapt our laboratory setting more closely to a typical clini-
cal situation, we decided to apply argon two and three hours
after trauma. We incubated the slices in an atmosphere con-
taining 50% argon because this concentration showed the
best neuroprotective effect after TBI and there was no signifi-
cant difference detectable between these three concentra-
tions in OGD. As before, we could show that Argon strongly
reduced cell damage in OGD and likewise in TBI (see Figure
4, panels A and B, respectively). Although there was an
increase in tissue damage when argon application was
delayed, argon was still significantly neuroprotective even two
and three hours after injury.
Discussion
We investigated the potential neuroprotective effects of the
noble gas argon in two in vitro models of OGD and TBI. Our
methods involved depriving cultured hippocampal slices of
oxygen and glucose or producing a focal mechanical trauma
on the CA1 region. Our data demonstrate argon's neuropro-
tective effect when it was applied directly as well as two and
three hours after trauma.Critical Care    Vol 13 No 6    Loetscher et al.
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Figure 1
Control data Control data. After preparation, 14 days of cultivation and baseline fluorescence imaging, slices were either impaired with oxygen-glucose depriva-
tion (OGD) or traumatic brain injury (TBI) (see panel A or B respectively). For OGD, the slices were incubated in glucose free medium and trans-
ferred into an airtight anoxic chamber where they were incubated in an atmosphere of 95% N2 and 5% CO2 for 30 minutes. TBI was induced by the 
impact of a stylus onto the CA1 region of the hippocampus. After trauma, the slices were transferred to an airtight chamber and incubated in an 
atmosphere of 21% O2, 5% CO2 and 74% N2. The negative control groups' slices were subjected to the same treatment, except for the trauma. 
After 72 hours the damage was assessed by fluorescence imaging and pixel-based image analysis. In both panels, both curves labelled as a show 
the histogram of non-traumatized slices (OGD: n = 58 prepared from six mice; TBI: n = 35 prepared from six mice) after 72 hours. The middle line is 
the mean value; the upper and lower lines represent the upper and lower bounds of the SEM. Curves b present the histogram of traumatized slices 
(OGD: n = 71 prepared from eight mice; TBI: n = 39 prepared from six mice). The vertical dashed line is the applied threshold at a gray scale value 
of 100. The sum over all pixel values greater than this threshold were calculated for each group and defined as the trauma intensity. Inserts in panel 
A and B respectively present the controls normalized to the trauma groups.Available online http://ccforum.com/content/13/6/R206
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Cultured organotypic hippocampal slices are a well estab-
lished [27,28] in vitro model to gain easy access to nerve tis-
sue. This model presents a reasonable compromise between
dissociated cell cultures and models using intact living animals
as most neuronal and glial cells survive [27] and their cytoar-
chitecture and connective organisation are well preserved
[18,23,28-32]. Reducing the complex functions of the in vivo
state to in vitro settings bears both benefits and disadvan-
tages which have to be taken into account when interpreting
our findings. However, this model mirrors to a certain extent
the in vivo characteristics, when complicating systemic factors
like blood pressure are excluded.
Utilization and outcome of OGD as a model of ischemia have
proven to be very reproducible and are widely used [4,33-36].
While the complete pathogenic pathways of stroke are still
incompletely understood, several mechanisms (including
increased glutamate, calcium overload, mitochondrial dysfunc-
tion and oxidative stress) have been proposed to contribute to
neuronal damage [28]. OGD, in contrast to other in vitro
ischemic models such as glutamate excitotoxicity, might be
more suitable to mimic this in vivo situation, as it allows for
more than one pathomechanism elicited by energy depletion
to occur. Although a wide range of possible neuroprotective
compounds such as glutamate receptor antagonists [37], cas-
pase inhibitors [38], anticonvulsants [39] and volatile anaes-
thetics [40] have been tested in an OGD setting, inert gases
other than xenon have heretofore been scarcely investigated.
Consequently, limited data are available on argon's organ-pro-
tective potential. Yarin [3] showed that argon protects rat's
hair cells against ototoxic processes. In another rat model, Sol-
datov and co-workers [2] found that a gas mixture containing
25% argon improved the animals' survival under hypoxic con-
ditions compared to a similar respiratory gas mixture without
argon.
Jawad et al. [4] were the first investigators to show that 75%
argon, administered during OGD and 24 hours thereafter, had
neuroprotective effects. However, these results were limited
to cultures of dissociated neurons. Therefore we used slice
cultures in our study as a more complex and lifelike model. We
could confirm argon's neuroprotective potential, even when
administered after trauma. Furthermore, we could establish a
concentration-dependent effect using three different argon
concentrations. There was no significant difference in neuro-
protective efficacy between the different argon concentrations
in the OGD setting. However, there was a peak effect at 50%
argon in the TBI-model. Interestingly, a similar observation
about a peak effect of 50% xenon in the same in vitro model
has been made by Coburn and colleagues. Yet, this was a the-
oretical assumption based on extrapolated data [8]. More
importantly, with regard to typical clinical situations, we could
demonstrate that argon significantly reduced neuronal dam-
age even when applied two or three hours after OGD.
The possible effects of argon on TBI were completely
unknown. Therefore we tested argon's impact in an in vitro
model by inducing a focal mechanical trauma. This model has
been widely used before by us and others when testing possi-
ble treatments [8,19,25] for traumatic brain injury. Neverthe-
less this is a simplified imitation of brain trauma, which lacks
pathomechanisms involving systemic variables (for example,
blood pressure) or local swelling, inflammation, ischemia and/
or hypoxia. Yet, despite these obvious limitations, it approxi-
Figure 2
Neuroprotective effects of argon Neuroprotective effects of argon. Following trauma (OGD or TBI), 
slices were incubated for 72 hours in an atmosphere containing either x 
= 25, 50 or 74% argon in addition to 21% O2, 5% CO2 and 74-x% N2. 
After fluorescence imaging and image analysis all groups were normal-
ized to their respective trauma control group at t = 72 hours. Panel A 
shows the results for OGD. For each group an average of 55 slices 
with a minimum of 42 slices was used (prepared from four to six mice). 
The trauma intensity in each argon group was significantly lower com-
pared to the trauma control group (*P ≤ 0.001), while there was no sig-
nificant difference amongst the different argon groups. Panel B shows 
the results for TBI. An average of 43 slices and a minimum of 35 slices 
was used for each group (prepared from four to eight mice). The 
detected trauma for each argon concentration was significantly lower 
compared to the control group (*P ≤ 0.001). Furthermore there was a 
significant difference between the three argon gas mixtures (P ≤ 0.004 
between 25% and 74% Argon and P ≤ 0.001 between 50% and 74% 
argon).Critical Care    Vol 13 No 6    Loetscher et al.
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mates the in vivo situation thereby validating its clinical feasi-
bility [41]. It is generally accepted that TBI damage is caused
by two main factors. The initial lesion is mediated through
direct mechanical damage at the impact site. Subsequently,
several cellular and molecular processes expand the local
injury. The so-called secondary injury is amongst others
caused by excitotoxicity [42], up-regulation of cell-death genes
[43], the formation of free radicals and the activation of pro-
apoptotic mediator pathways [44-46].
Since medical intervention cannot rescue directly traumatized,
dying cells, cells near the impact site surviving the initial
assault are the main target for the neuroprotective potential of
drugs [43]. Indeed, our experiments showed that argon was
able to reduce cell death significantly, whether it was applied
directly after the trauma or two and three hours afterwards. Of
particular significance is argon's potential in protecting neuro-
nal cells when argon administration was delayed. One of the
many reasons why positive in vitro results do not transfer
favourably to clinical trials [47] is that in many laboratory mod-
els treatment is only applied during the course of injury or
directly thereafter. We decided to explore the outcome of
delayed argon application solely with a gas mixture containing
50% argon for two reasons. First, in the TBI setting 50% argon
was most effective. Secondly, and clinically more relevant,
50% of argon allows a higher inspiratory oxygen concentration
for patients who require it.
Of consequence, especially in times of cost reduction, argon
is the most abundant inert gas which is already widely used in
other industries and therefore available at a relatively low price
(nine cents/l) compared to xenon (20 €/l). Furthermore, argon
has no anaesthetic properties at normobaric conditions [48]. It
may therefore be used when sedation would be inappropriate.
While to date little is known about argon's mechanism of
action, it has been proposed that argon triggers gamma-ami-
nobutyric acid (GABA) neurotransmission by acting at the
benzodiazepine binding site and possibly at multiple other dis-
crete sites of the GABAA receptor [49]. The activation of
GABA receptors has been shown to be neuroprotective in in
vitro and in vivo ischemia models and several potential mech-
anisms have been proposed [40,50]. First, glutamatergic and
GABAergic activity counterbalance the function of each other.
On an electrochemical level, stimulation of the ionotropic
GABAA receptor and the following chloride-based membrane
Figure 3
Example images Example images. Panels A and B show example images for both OGD (panel A) and TBI (panel B). From left to right: No Trauma, 50% Argon, 
Trauma control.Available online http://ccforum.com/content/13/6/R206
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hyperpolarization inhibit N-methyl-D-aspartate (NMDA) recep-
tors [51]. In an in vivo rat model, Zhang et al. could show that
GABA receptor activation diminished the phosphorylation of
the NR2A subunit of the NMDA receptor, thus directly attenu-
ating the receptors functionality [52]. NMDA receptor activa-
tion is generally seen as a key element in the development of
neuronal death following ischemic events by, among others,
increasing calcium influx [53,54]. Second, GABA receptor
activation directly influences downstream pathogenic path-
ways. Galeffi et al. showed that diazepam counteracted ATP
depletion and disabled cytochrome c release in rat hippocam-
pal slices after OGD, two main events in the ischemic cascade
[55]. Xu and co-workers demonstrated that GABA agonists
inhibited pro-apoptotic pathways through activation of the
phosphoinositide 3-kinase/protein kinase B cascade [56].
These findings can be a starting point for further studies to
describe argons definite mode of action.
Nevertheless it is surprising that noble gases are able to gen-
erate an effect as it requires forming a chemical bond with
another molecule. The gas molecules' outer valence shell is
completely filled with electrons, making the gas inert to basic
chemical reactions. However, these freely vacillating electrons
can be polarized. Trudell et al. suggest that a charged element
of the binding site itself can induce a bipole in the gas mole-
cules, thus generating enough binding energy to form a bond
with the binding site. Another component of the binding
energy might be the London dispersion force which is gener-
ated by changes in electron density. When the distribution of
electrons in one molecule fluctuates to produce an instantane-
ous dipole, this dipole can produce a dipole in a second mol-
ecule [57]. Thus, the previously uncharged gas molecules are
temporarily polarized and therefore enabled to interact with
the binding site.
Conclusions
This study shows that argon bears surprisingly effective neu-
roprotective potential in both in vitro models of ischemia and
traumatic brain injury. Protection was observed with three dif-
ferent concentrations of argon (25, 50 and 74%), either
directly applied after the trauma or when administered at a
concentration of 50% two and three hours after the injuries.
Considering these promising results, despite the inherent sim-
plifications of any in vitro model, further animal research, pref-
erably using a whole animal model, seems appropriate.
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Figure 4
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72 hours in an atmosphere of 50% Argon, 21% O2, 5% CO2 and 24% 
N2, either directly after trauma was induced (t = 0) or with a two or 
three hours delay. All groups were normalized to their respective 
trauma control group at t = 72 hours. Panel A shows the results for 
OGD and panel B the results for TBI. In the OGD group an average of 
43 slices with a minimum of 22 slices was used (prepared from three 
mice per group). We found a significant difference between the control 
group and each tested time point (*P ≤ 0.001). Moreover the trauma 
intensity between t = 0 hours and t = 3 hours differed significantly (P ≤ 
0.05). In the TBI group the detected trauma after zero, two and three 
hours delay time was significantly lower compared to the trauma con-
trol group (*P ≤ 0.001). Furthermore, trauma intensity after three-hour 
delay time was significantly increased as compared to zero and two-
hour delay (P ≤ 0.001). An average of 31 slices and a minimum of 15 
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